Clopidogrel Acino Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiske midler - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Acino Pharma Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.

Clopidogrel Acino Pharma GmbH Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.